ANGO stock forecast, quote, news & analysis
AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses... Show more
Why AngioDynamics (ANGO) Stock Is Down -24.8% in the Last 30 Days
Key Takeaways
- AngioDynamics (ANGO) shares declined roughly 24.8% over the 30 days through early October 2026, closing near $11.52 versus about $15.32 a month earlier.
- The move was concentrated around the fiscal 2027 first-quarter earnings release: the stock fell about 21% in a single session even as results beat expectations.
- The company's Med Tech segment grew 13.2% year over year, marking an eighth consecutive quarter of double-digit growth, but investors focused on a still-loss-making bottom line.
- Management reiterated fiscal 2027 guidance and announced a planned CEO transition, adding to near-term uncertainty.
- Over the trailing three months, shares climbed from roughly $13 to a peak near $16 in late August before reversing sharply.
AngioDynamics (ANGO) Company Overview and Market Position
AngioDynamics, Inc. is a medical technology company headquartered in Latham, New York, focused on restoring healthy blood flow in the vascular system, expanding cancer treatment options, and improving patient quality of life. The company operates through two reporting segments: Med Tech and Med Device.
The higher-growth Med Tech segment includes the Auryon peripheral atherectomy platform, the AlphaVac and AngioVac mechanical thrombectomy (clot removal) systems, and the NanoKnife irreversible electroporation (IRE) platform used primarily in prostate and liver cancer treatment. The Med Device segment consists of established catheter, port, and vascular access products that generate consistent cash flow and fund investment in the growth platforms. Investors follow ANGO for its multi-year transformation toward higher-margin Med Tech products, which now account for roughly half of total revenue.
AngioDynamics (ANGO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ANGO shares fell approximately 24.8%, from a closing price of about $15.32 in early September 2026 to roughly $11.52 in early October. The decline was heavily concentrated in the days surrounding the company's first-quarter fiscal 2027 earnings report, when the stock lost about 21% in a single trading session.
The broader quarterly picture is more nuanced. Shares began the period around $13 in early July, rallied to an intra-quarter high near $16 by late August on sustained Med Tech momentum and favorable NanoKnife reimbursement catalysts, then faded through September before the sharp October selloff. On a trailing three-month basis, ANGO is down roughly 11%, reflecting a full round trip from the summer rally back below its starting point.
What Drove ANGO Stock Price in the Last 30 Days
The primary catalyst was the fiscal 2027 first-quarter earnings report released in early October 2026. Revenue rose 6.9% year over year to $80.9 million, and adjusted loss per share of $0.04 beat the consensus estimate of a $0.11 loss by roughly 60%. Med Tech revenue grew 13.2% to $39.9 million, led by Auryon (up 14.7%, its 21st consecutive quarter of double-digit growth), NanoKnife (up 29%), and AlphaVac (up 37.4%). Gross margin expanded 410 basis points to 59.4%, helped in part by tariff refunds.
Despite the beat, the stock dropped sharply. The company still recorded a GAAP net loss of $7.1 million, used $15.3 million of cash from operations in the quarter, and saw its cash balance decline to about $33.9 million. Management reiterated full-year guidance that still implies adjusted losses, and announced that Eric Honroth would succeed Jim Clemmer as CEO effective November 2, 2026. The market appeared to weigh ongoing execution, reimbursement, and competitive risks against the improving Med Tech mix, driving a sharp de-rating of the shares.
What Drove ANGO Stock Performance Over the Last Quarter
The quarterly trend was shaped by a broader narrative around the company's strategic transformation. In mid-July 2026, ANGO reported record fiscal fourth-quarter and full-year results, with fiscal 2026 revenue of $320.2 million (up 9.4%) and Med Tech sales of $150.0 million (up 18.4%). The stock rallied on those results and on a series of NanoKnife catalysts, including the activation of Category I CPT codes for prostate and liver IRE procedures and a Palmetto GBA local coverage determination supporting Medicare reimbursement effective July 2025.
Positive clinical developments, including two-year PRESERVE trial data presented at the American Urological Association and FDA approvals for the RELIEF benign prostatic hyperplasia study and additional thrombectomy trials, reinforced the growth story through the summer. However, the rally stalled as investors increasingly weighed the company's persistent losses and cash usage against its revenue momentum, setting the stage for the October post-earnings decline.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots that have demonstrated notable recent performance. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only top-performing and most relevant bots are featured in this section, giving users a focused view of strategies attracting attention at any given time. These bots vary in strategy, timeframe, and performance metrics, so they can serve different trading styles and risk profiles. Exploring the curated list can help traders identify automated approaches worth monitoring alongside their own research.
ANGO Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors in the quarters ahead. Key among them is execution against fiscal 2027 guidance of $336 million to $341 million in revenue, Med Tech growth of 12% to 15%, gross margin of 54% to 55%, adjusted EBITDA of $13 million to $16 million, and adjusted EPS between a loss of $0.29 and $0.24. The leadership transition to a new CEO in November 2026 will also be closely watched for any strategic shifts.
Further expansion of NanoKnife Medicare coverage across additional regions, continued enrollment in the APEX-Return, PAVE, AMBITION BTK, and RELIEF clinical studies, and the company's progress toward sustained profitability and positive operating cash flow are likely to be central to the stock's direction. Macroeconomic factors, including tariffs and reimbursement dynamics, remain relevant risks to monitor.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ANGO in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 06, 2026
ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 33 cases where ANGO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANGO's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in 197 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANGO as a result. In 65 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
ANGO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for ANGO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.877) is normal, around the industry mean (4.952). P/E Ratio (-13.511) is within average values for comparable stocks, (36.644). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.005) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ANGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians
Industry PharmaceuticalsOther